Drug Utilization Review of Dipeptidyl Peptidase–4 (DPP-4) Inhibitors on adult patients with Type 2 Diabetes Mellitus (T2DM) in Caritas Medical Centre

This abstract has open access
Abstract Description
Abstract ID :
HAC791
Submission Type
Authors (including presenting author) :
Lo EHY(1), Fung PP(1)
Affiliation :
(1)Department of Pharmacy, Caritas Medical Centre
Introduction :
Dipeptidyl Peptidase-4 inhibitors are classified as special drugs within the Hospital Authority Drug Formulary (HADF) for the management of Type 2 Diabetics Mellitus (T2DM). They are considered as alternative to insulin after failure of optimal doses of sulphonylurea (SU) and metformin, or optimal doses of SU if metformin is intolerable /contraindicated; or as adjunctive to insulin to optimize control. DPP-4 inhibitor therapy should be discontinued if it fails to achieve HbA1c less than 8% within 6-8 months.
Objectives :
 To evaluate prescribers’ compliance to the recommendations listed in the HADF version 13.3 on initiation and discontinuation of DPP-4 inhibitors in adults with T2DM
 To evaluate the utilization pattern and assess the safety and efficacy of DPP-4 inhibitors
Methodology :
This was a single-centered, retrospective study. Medicines & Geriatric Specialist Out-Patient Clinic patients who were prescribed with DPP-4 inhibitors between 1 Sep 2016 and 31 Oct 2017 were included in the study. Recruited cases were reviewed to determine whether the initiation and continuation of DPP-4 inhibitors was in accordance to HADF recommendations. The appropriateness of dosage was reviewed with regard to renal function and concurrent medications. The efficacy of DPP-4 inhibitor was assessed by the change of HbA1c before and after treatment.
Result & Outcome :
294 patients were recruited in the study and 290 (98.6%) were indicated to initiate DPP-4 inhibitors as special drug. Among those patients, 278 (94.6%) had the DPP-4 inhibitors continued after 6-8 months in which, 152 (54.6%) were considered appropriate and 121 (43.5%) inappropriate. The mean change of HbA1c after 6-8 months was -1.0%. Almost all patients in the linagliptin and sitagliptin groups were prescribed with appropriate dosage. In the vildagliptin group, 46 (29.3%) were prescribed with inappropriate dosage. All of these patients received concomitant SU in which the dose of vildagliptin should be adjusted. Most patients had DPP-4 inhibitors initiated as indicated however only about half were continued appropriately. The efficacy of DPP-4 inhibitors was found similar to other literature. Almost all patients received appropriate dosage with respect to their renal function. When given with concurrent SU, one-third of the vildagliptin group did not have the dosage reduced.

Abstracts With Same Type

Abstract ID
Abstract Title
Abstract Topic
Submission Type
Primary Author
HAC720
Clinical Safety and Quality Service I
HA Staff
Maria SINN Dr
HAC456
Enhancing Partnership with Patients and Community
HA Staff
Donna TSE
HAC1262
Enhancing Partnership with Patients and Community
HA Staff
S F LEE Dr
HAC997
Clinical Safety and Quality Service II
HA Staff
K L CHAN
385 visits